Go to Health Care Provider version
| Diagnosis | Retinoblastoma | Study Status | Closed to enrollment |
| Phase | I |
| Age | Child - (up to 17 Years) | Randomisation | NO |
| Line of treatment | First line treatment, Disease relapse or progression |
| Routes of Treatment Administration | Topotecan - administered using an episcleral plaque (chemoplaque), an implant which contains topotecan (drug).
The implant is attached to the outside of the eye and delivers topotecan directly into the eye.
|
| Last Posted Update | 2024-01-09 |
| ClinicalTrials.gov # | NCT04428879 |
International Sponsor
The Hospital for Sick Children
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Daniel MorgensternCentres
Study Description
This clinical trial studies the side effects and how well a chemoplaque with topotecan (a medication attached to the outside of the eye) works in treating patients with retinoblastoma. This plaque has to be installed and removed under general anesthesia by the ophthalmology team. It delivers the chemotherapy inside the eye.
Inclusion Criteria
- Age up to 18 years
- Retinoblastoma in at least one eye
- Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team
